Q-omics provides the consensus-scored B3GALT4 profile across patient tissues and cancer cell-line models. B3GALT4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SARC. Among the 18 cancer types available for tumor–normal comparison, B3GALT4 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, B3GALT4 RNA expression shows 16,680 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SARC, COAD, and ACC as cancer lineages where B3GALT4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for B3GALT4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes B3GALT4 survival associations across molecular data types. B3GALT4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible B3GALT4 RNA expression–survival associations across cancer types. High B3GALT4 expression shows unfavorable associations in UVM and LGG, but favorable associations in SARC, THCA, SCLC and MESO. The SARC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SARC as the clearest survival context for B3GALT4 RNA expression.
This table summarizes B3GALT4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for B3GALT4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. B3GALT4 shows lower tumor expression in COAD, KICH, READ, KIRP, UCEC and LUAD. The COAD box plot shows higher B3GALT4 RNA expression in normal versus tumor tissue (log2 FC = −1.320, t-test p < 0.001).
This table shows molecular features associated with B3GALT4 in patient tissues and cancer cell lines. In patient samples, B3GALT4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, B3GALT4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
